Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 10;8(2):3042-3048.
doi: 10.18632/oncotarget.13824.

Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus

Chin-Hsiao Tseng  1   2   3
Affiliations

Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus

Chin-Hsiao Tseng. Oncotarget. .

Abstract

This study investigated whether rosiglitazone may affect breast cancer risk in female patients with type 2 diabetes mellitus in Taiwan. The reimbursement database of all female patients with type 2 diabetes mellitus under oral antidiabetic agents or insulin from 1996 to 2009 was retrieved from the National Health Insurance. An entry date was set on 1 January 2006 and a total of 431447 patients were followed up for breast cancer incidence till the end of 2009. Incidences for ever users, never users and subgroups of rosiglitazone dose-response parameters (tertile cutoffs of cumulative duration and cumulative dose) were calculated and hazard ratios estimated by Cox regression. There were 53029 ever users and 378418 never users, respective numbers of incident breast cancer 410 (0.77%) and 3292 (0.87%), and respective incidence 217.53 and 249.12 per 100000 person-years. The overall hazard ratio was 0.889 (95% confidence interval: 0.797-0.992) in the fully adjusted model. Significantly lower risk was observed for the third tertiles of cumulative duration (> 14 months) and cumulative dose (> 1792 mg) while compared to never users, with respective adjusted hazard ratio of 0.815 (95% confidence interval: 0.682-0.973) and 0.815 (95% confidence interval: 0.682-0.974). Additionally, a significant interaction between metformin and rosiglitazone was observed. The lowest risk was seen in patients who used both drugs (hazard ratio 0.812, 95% confidence interval: 0.705-0.934). In conclusion, rosiglitazone reduces breast cancer risk in female patients with type 2 diabetes mellitus, which shows a significant interaction with metformin.

Keywords: Taiwan; breast cancer; diabetes mellitus; rosiglitazone.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The author declares no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kotta-Loizou I, Giaginis C, Theocharis S. The role of peroxisome proliferator-activated receptor-γ in breast cancer. Anticancer Agents Med Chem. 2012;12:1025–44. - PubMed
    1. Bojková B, Garajová M, Kajo K, Péc M, Kubatka P, Kassayová M, Kisková T, Orendás P, Ahlersová E, Ahlers I. Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev. 2010;19:379–84. - PubMed
    1. Kocdor H, Kocdor MA, Canda T, Gurel D, Cehreli R, Yilmaz O, Alakavuklar M, Guner G. Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis. Clin Transl Oncol. 2009;11:243–9. - PubMed
    1. Cheng WY, Huynh H, Chen P, Peña-Llopis S, Wan Y. Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. Elife. 2016;3:5. - PMC - PubMed
    1. Hatton JL, Yee LD. Clinical Use of PPARgamma Ligands in Cancer. PPAR Res. 2008;2008:159415. - PMC - PubMed

MeSH terms